Ono Pharma buys rights to Equillium's itolizumab

6 December 2022
ono-pharma-logo

Shares of La Jolla USA-based biotech Equillium (Nasdaq EQ) were up 12% to $1.85 in pre-market trading, on news of a lucrative licensing deal with Japan’s Ono Pharmaceutical (TYO: 4528)

The companies have entered into an exclusive option and asset purchase agreement regarding Equillium’s rights to itolizumab, a first-in-class anti-CD6 monoclonal antibody, to which the US firm gained rights through an exclusive partnership with India’s Biocon.

Itolizumab is currently in a Phase III study for patients with acute graft-versus-host disease and in a Phase Ib study for patients with lupus nephritis

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology